Showing results (1-10 of 111) with videos related to
Sort By:
Pageof 12
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 14, 2019
Delivering on the Promise of BiosimilarsArnold G VultoExpert Opinion on Biological Therapy|November 18, 2020
A health economic guide to market access of biosimilarsSteven Simoens, Arnold G VultoRheumatology (Oxford, England)|September 15, 2017
The process defines the product: what really matters in biosimilar design and production?Arnold G Vulto, Orlando A JaquezTargeted Oncology|January 26, 2012
Risk management of biosimilars in oncology: each medicine is a work in progressArnold G Vulto, Stacy A CrowActa Clinica Belgica|May 14, 2020
Biosimilars in Belgium: a proposal for a more competitive marketEvelien Moorkens, Arnold G Vulto, Isabelle HuysMabs|April 21, 2020
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?Evelien Moorkens, Arnold G Vulto, Isabelle HuysExpert Review of Pharmacoeconomics & Outcomes Research|April 25, 2014
Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainabilityPieter Dylst, Arnold G Vulto, Steven SimoensPharmaceuticals (Basel, Switzerland)|June 2, 2021
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case StudySteven Simoens, Arnold G Vulto, Pieter DylstBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 16, 2020
European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical PracticeLiese Barbier, Steven Simoens, Arnold G Vulto, et al.Acta Ophthalmologica|April 30, 2026
Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time-series analysisElif Car, Isabelle Huys, Steven Simoens, et al.Pageof 12